Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01583374 · ClinicalTrials.gov registry record · Phase 3
Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 490
- Enrollment target
NCT01583374 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 490 participants.
The verdict
NCT01583374, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 490 participants
- Enrollment target
Study Summary
Apremilast is a new, orally available, small molecule drug that specifically inhibits phosphodiesterase 4 (PDE4), an enzyme that modulates inflammatory cytokines. This clinical study tests whether apremilast can improve the signs and symptoms of ankylosing spondylitis.
Interventions
- DRUG Placebo
- DRUG Apremilast tablet 20 mg
- DRUG Apremilast tablet 30 mg BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2012-05-02 |
| Est. Completion | 2018-10-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01583374
The ClinicalTrials.gov registry entry for NCT01583374 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 490 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01583374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01583374 about?
NCT01583374 is a clinical study titled "Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis". Apremilast is a new, orally available, small molecule drug that specifically inhibits phosphodiesterase 4 (PDE4), an enzyme that modulates inflammatory cytokines. This clinical study tests whether apremilast can improve the signs and symptoms of ankylosing spondylitis.
What is the current status of trial NCT01583374?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 490 participants. The study started on 2012-05-02. Estimated completion is 2018-10-25.
What interventions are being tested in trial NCT01583374?
The interventions under investigation include: Placebo (DRUG), Apremilast tablet 20 mg (DRUG), Apremilast tablet 30 mg BID (DRUG).
Who is sponsoring clinical trial NCT01583374?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.